Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change that story is the question every shareholder now faces.